Loading...
Progress has been made in the treatment of patients with advanced pancreatic cancer, with combination chemotherapy modestly improving overall survival compared with single-agent gemcitabine. However, after FOLFIRINOX or gemcitabine-based first-line chemotherapy, there is no standard second-line chemotherapy.
Investigators now report results of the NAPOLI-1 trial, an industry-sponsored, global, open-label, randomized phase III study of nanoliposomal-encapsulated irinotecan in 417 patients with pancreatic cancer who experienced disease progression with gemcitabine-based chemotherapy. Patients were randomized to receive nanoliposomal irinotecan monotherapy; 5-fluorouracil (5-FU) plus folinic acid; or nanoliposomal irinotecan followed by folinic…